ClinicalTrials.gg
RecruitingNCT07699328REACH-EGFRUpdated Nov 6, 2026

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

A Phase 1/2 interventional study of VRN110755 in EGFR-Mutant Non-Small Cell Lung Cancer, sponsored by Voronoi, Inc. Recruiting at 29 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Voronoi, Inc · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Mar 2024, registered Jul 2026).
  • Started Mar 2024; still recruiting 2 years 7 months later.
Updated Nov 6, 2026Study contact changedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
315
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of — 123 open to participants now, 264 under way, 101 of them phase 3. Carcinoma, Non-Small-Cell Lung · Korea, Republic of.

Planned enrollment
240th of 657
315 · median 200
Started
2024
with 54 others
Phase 1/2
84 of 700
25 open now
Primary completion
2029-01
later than 205 of 263 live
Registered
696th of 700
by date

Among the 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, this one is the 240th largest by planned enrollment of the 657 interventional ones that give a count, is one of 55 that started in 2024, is one of 84 in phase 1/2, reaches primary completion later than 205 of the 263 other live ones, and was the 696th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

123 of the 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC).

The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.

Read the detailed description

This is a Phase 1/2, multicenter, open-label, non-randomized, dose-escalation and dose-expansion clinical trial evaluating VRN110755 administered as oral monotherapy once daily in 28-day treatment cycles.

Phase 1a uses a standard 3+3 dose-escalation design to evaluate safety, tolerability, dose-limiting toxicities, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity and to determine the maximum tolerated dose (MTD).

Phase 1b evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity across molecularly defined EGFR-mutant NSCLC cohorts and determines the recommended Phase 2 dose (RP2D).

Following determination of the RP2D, selected expansion cohorts will continue into the Phase 2 portion to further evaluate the efficacy, safety, tolerability, and pharmacokinetics of VRN110755. The specific Phase 2 cohorts will be selected based on the safety and efficacy data generated during Phase 1b.

Participants remain on treatment until disease progression, unacceptable toxicity, withdrawal of consent, initiation of another anticancer therapy, death, or study completion.

03

Conditions studied

  • EGFR-Mutant Non-Small Cell Lung Cancer

Keywords

  • NSCLC
  • EGFR
  • Epidermal Growth Factor Receptor
  • Non-Small Cell Lung Cancer
  • EGFR Mutation
  • C797S
  • EGFR Tyrosine Kinase Inhibitor Resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older (19 years or older in the Republic of Korea).
  • Able to understand, sign, and provide written .
  • or cytologically confirmed advanced, , or recurrent predominantly nonsquamous non-small cell lung cancer (NSCLC) with a documented epidermal growth factor receptor (EGFR) mutation.
  • At least one measurable extracranial lesion according to (RECIST) Version 1.1.
  • Documented EGFR mutation determined by tumor tissue or liquid .
  • (ECOG) performance status of 0 or 1.
  • Able to swallow oral capsules and comply with study procedures.
  • Women of must have a negative pregnancy test, must not be breastfeeding, and must agree to use effective during the study and for 7 months after the last safety follow-up visit. Men must agree to use effective contraception during the study and for 6 months after the last safety follow-up visit.
  • No appropriate standard treatment options are available or standard treatment is not considered feasible, in the opinion of the investigator.
  • Participants must meet the disease-specific eligibility criteria for one of the following study groups:

    • Phase 1a

      • NSCLC with EGFR activating, resistant, uncommon, or complex mutations, including but not limited to exon 19 deletion (Del19), L858R, C797S, or other uncommon EGFR mutations.
      • Radiographic disease progression following at least 2 cycles of prior EGFR tyrosine kinase inhibitor (TKI) therapy or discontinuation of prior EGFR TKI therapy because of toxicity, with no remaining standard therapy expected to provide clinical benefit.
    • Phase 1b - Cohort A

      • NSCLC with EGFR exon 19 deletion or L858R mutation plus a C797X resistance mutation following disease progression after treatment with a third-generation EGFR TKI (including osimertinib, lazertinib, or aumolertinib).
    • Phase 1b - Cohort B

      • Treatment-naïve NSCLC with common EGFR mutations.
    • Phase 1b - Cohort C

      • NSCLC with atypical or uncommon EGFR mutations (including G719X, L861Q, S768I, E709X, R776H, L747S, or combinations of these mutations) previously treated with at least one systemic therapy, including an EGFR TKI, with no remaining standard therapy expected to provide clinical benefit.
    • Phase 1b - Cohort D

      • Treatment-naïve NSCLC with atypical EGFR mutations.

Exclusion criteria

Exclusion Criteria:

  • Received an anticancer therapy within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment.
  • Unresolved side effects from previous anticancer therapy greater than Grade 1 according to the National Cancer Institute (CTCAE), except for Grade 2 peripheral neuropathy or alopecia.
  • Pregnant or breastfeeding, or planning to become pregnant during the study.
  • NSCLC with an EGFR or exon 20 insertion mutation.
  • Another active within the past 3 years, with the exception of adequately treated cancers considered cured.
  • Inadequate bone marrow, kidney, or liver function based on protocol-defined laboratory criteria.
  • Active infection requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before the first dose of study treatment.
  • Active or infection, or known (HIV) infection.
  • Receipt of a within 4 weeks before the first dose of study treatment.
  • Use of strong or moderate cytochrome P450 (CYP) 3A inhibitors or inducers, certain herbal supplements, or other prohibited medications within the protocol-defined .
  • Major surgery within 4 weeks before the first dose of study treatment or incomplete recovery from major surgery.
  • Receipt of prior anticancer therapy within the protocol-defined washout period, including systemic therapy, immunotherapy, or radiotherapy.
  • Symptomatic or uncontrolled central nervous system (CNS) or spinal cord compression requiring increasing doses of . Participants with treated and stable or asymptomatic CNS disease may be eligible.
  • Requirement for systemic corticosteroid therapy exceeding the protocol-defined limit.
  • cardiovascular disease, including prolonged , clinically significant arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, uncontrolled hypertension, reduced , or use of medications known to prolong the QT interval.
  • History of interstitial lung disease, noninfectious pneumonitis requiring steroid treatment, or current interstitial lung disease or pneumonitis.
  • Inability to swallow oral capsules or gastrointestinal disorders that may interfere with absorption of study treatment.
  • Known allergy or to VRN110755 or any of its components.
  • Alcohol or drug abuse within the previous 2 years or any medical, psychological, or social condition that, in the opinion of the investigator, would interfere with study participation or interpretation of study results.
  • Use of proton pump inhibitors, histamine-2 receptor antagonists, or locally acting antacids within the protocol-defined washout period or inability to comply with protocol requirements for acid-reducing medications.
  • For Phase 1b and Phase 2 only: Presence of another targetable oncogenic driver alteration with an approved targeted therapy, including MET or HER2 amplification; ALK, ROS1, NTRK, or RET fusion; or BRAF V600E or KRAS G12X mutation.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
315 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    Participants with advanced, metastatic, or recurrent EGFR-mutant non-small cell lung cancer (NSCLC) who have experienced disease progression following prior EGFR tyrosine kinase inhibitor (TKI) therapy and harbor activating, resistant, uncommon, or complex EGFR mutations. Participants receive escalating dose levels of VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity and to determine the maximum tolerated dose (MTD).

    Drug: VRN110755

  • Experimental
    Phase 1b Cohort A

    Participants with EGFR-mutant NSCLC harboring exon 19 deletion or exon 21 L858R mutations and a C797X resistance mutation following progression on first-line third-generation EGFR TKI therapy, including osimertinib, lazertinib, or aumolertinib. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity and to support selection of the recommended Phase 2 dose.

    Drug: VRN110755

  • Experimental
    Phase 1b Cohort B

    Treatment-naïve participants with NSCLC harboring common EGFR mutations. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity in patients who have not previously received systemic treatment for EGFR-mutant NSCLC.

    Drug: VRN110755

  • Experimental
    Phase 1b Cohort C

    Participants with NSCLC harboring atypical or uncommon EGFR mutations, including G719X, L861Q, S768I, E709X, R776H, L747S, or combinations thereof, who have previously received at least one prior systemic therapy, including an EGFR TKI, and have no remaining standard treatment options expected to provide clinical benefit. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity.

    Drug: VRN110755

  • Experimental
    Phase 1b Cohort D

    Treatment-naïve participants with NSCLC harboring atypical EGFR mutations. Participants receive VRN110755 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity in patients who have not previously received systemic treatment for EGFR-mutant NSCLC.

    Drug: VRN110755

Interventions

  • DrugVRN110755

    VRN110755 is an investigational highly selective oral EGFR inhibitor supplied as capsules for oral administration. The drug is designed to target activating EGFR mutations and selected resistance mutations, including C797S, in patients with EGFR-mutant NSCLC.

06

What researchers measure

Primary outcomes

  1. Estimate of Maximum Tolerated Dose (MTD) of VRN110755

    This will be based on dose-limiting toxicities (DLTs) observed during the DLT evaluation period.

    Time frame: 28 days

  2. Number of participants with dose-limiting toxicities (DLTs) following treatment with VRN110755

    Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria during the DLT evaluation period.

    Time frame: 28 days

  3. Number of participants experiencing treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation

    Time frame: From first dose until end of study (up to approximately 6 years)

  4. Number of participants with changes in vital signs from baseline following treatment with VRN110755

    Vital signs include blood pressure, pulse rate, respiratory rate, body temperature, and oxygen saturation.

    Time frame: From baseline through End of Treatment (up to approximately 6 years)

  5. Number of participants with changes in laboratory test results from baseline following treatment with VRN110755

    Laboratory evaluations include hematology, clinical chemistry, coagulation, and urinalysis assessments.

    Time frame: From baseline through End of Treatment (up to approximately 6 years)

  6. Number of participants with changes in physical examination findings from baseline following treatment with VRN110755

    Physical examinations include complete physical examinations at screening and End of Treatment and symptom-directed physical examinations during study treatment.

    Time frame: From baseline through End of Treatment (up to approximately 6 years)

  7. Number of participants with changes in ophthalmologic examination findings from baseline following treatment with VRN110755

    Ophthalmologic examinations include best corrected visual acuity, intraocular pressure, slit-lamp examination, spectral-domain optical coherence tomography (SD-OCT), confrontation visual fields, and fundoscopic examination.

    Time frame: From baseline through End of Treatment (up to approximately 6 years)

  8. Number of participants with changes in electrocardiogram (ECG) parameters from baseline following treatment with VRN110755

    Electrocardiogram assessments include 12-lead ECG parameters, including QT interval corrected using Fridericia's formula (QTcF).

    Time frame: From baseline through End of Treatment (up to approximately 6 years)

  9. Number of participants with changes in Eastern Cooperative Oncology Group (ECOG) Performance Status from baseline following treatment with VRN110755

    Time frame: From baseline through End of Treatment (up to approximately 6 years)

Secondary outcomes

  1. Plasma PK of VRN110755 - Maximum Plasma Concentration (Cmax)

    Maximum observed plasma concentration of VRN110755.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  2. Plasma PK of VRN110755 - Minimum Plasma Concentration (Cmin)

    Minimum observed plasma concentration of VRN110755.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  3. Plasma PK of VRN110755 - Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast)

    Area under the plasma concentration-time curve from time zero to the last measurable concentration of VRN110755.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  4. Plasma PK of VRN110755 - Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCτ)

    Area under the plasma concentration-time curve over the dosing interval at steady state for VRN110755.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  5. Plasma PK of VRN110755 - Time to Maximum Plasma Concentration (Tmax)

    Time from dosing to the maximum observed plasma concentration of VRN110755.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  6. Plasma PK of VRN110755 - Terminal Elimination Rate Constant (λz)

    Terminal elimination rate constant of VRN110755 estimated from the terminal log-linear portion of the plasma concentration-time curve.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  7. Plasma PK of VRN110755 - Apparent Terminal Elimination Half-life (t½)

    Apparent terminal elimination half-life of VRN110755 estimated from the terminal elimination phase of the plasma concentration-time curve.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  8. Plasma PK of VRN110755 - Apparent Volume of Distribution During the Terminal Phase (Vz/F)

    Apparent volume of distribution during the terminal elimination phase of VRN110755 following oral administration.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  9. Plasma PK of VRN110755 - Apparent Total Plasma Clearance (CL/F)

    Apparent total plasma clearance of VRN110755 following oral administration.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  10. Plasma PK of VRN110755 - Trough Plasma Concentration (Ctrough)

    Plasma concentration of VRN110755 immediately before the next scheduled dose at steady state.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  11. Plasma PK of VRN110755 - Mean Residence Time Based on AUClast (MRTlast)

    Mean residence time of VRN110755 in the body calculated based on AUClast.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  12. Plasma PK of VRN110755 - Accumulation Ratio (Rac)

    Accumulation ratio of VRN110755 following repeated once-daily dosing, calculated using protocol-specified pharmacokinetic parameters.

    Time frame: Predose and up to 24 hours postdose on protocol-specified pharmacokinetic sampling days.

  13. Change from Baseline in Circulating Tumor DNA (ctDNA)

    Change from baseline in circulating tumor DNA (ctDNA) levels, including EGFR Del19, L858R, Del19/C797S, L858R/C797S, C797S, and other protocol-specified EGFR mutations.

    Time frame: Screening, Day 1 of protocol-specified treatment cycles (each cycle is 28 days) and End of Treatment (up to approximately 6 years)

  14. Objective Response Rate (ORR)

    The proportion of participants whose best overall response is a confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: From first dose until end of study (up to approximately 6 years)

  15. Duration of Response (DOR)

    Duration of response (DOR), defined as the time from the first documented confirmed complete response or confirmed partial response until disease progression or death from any cause.

    Time frame: From first dose until end of study (up to approximately 6 years)

  16. Number of participants with Disease Control Rate (DCR)

    Disease control rate (DCR), defined as the proportion of participants achieving confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) according to RECIST Version 1.1.

    Time frame: From first dose until end of study (up to approximately 6 years)

  17. Progression-Free Survival (PFS)

    Progression-free survival (PFS), defined as the time from the first dose of study treatment until documented disease progression or death from any cause.

    Time frame: From first dose until end of study (up to approximately 6 years)

  18. Overall Survival (OS)

    Overall survival (OS), defined as the time from the first dose of study treatment until death from any cause.

    Time frame: From first dose until end of study (up to approximately 6 years)

  19. Intracranial Objective Response Rate (Intracranial ORR)

    The proportion of participants with brain metastases who achieve a confirmed intracranial complete response or partial response according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.

    Time frame: From first dose until end of study (up to approximately 6 years)

  20. Intracranial Progression-Free Survival (Intracranial PFS)

    Intracranial progression-free survival assessed according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria in participants with brain metastases.

    Time frame: From first dose until end of study (up to approximately 6 years)

07

Study locations

29 of 29 sites recruiting
  • Southern Oncology Clinical Research Unit
    Bedford Park, South Australia 05042, Australia
    Recruiting
    • Shawgi Sukumaran · Principal investigator
  • Monash Medical Centre Clayton
    Clayton, Victoria 3168, Australia
    Recruiting
    • Surein Arulananda · Principal investigator
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Natasha Leighl · Principal investigator
  • AP-HM Hôpital Nord
    Marseille, Bouches-du-Rhône 13915, France
    Recruiting
    • Pascale Tomasini · Principal investigator
  • Centre Georges François Leclerc
    Dijon, Côte-d'Or 21079, France
    Recruiting
    • François Ghiringhelli · Principal investigator
  • Prince of Wales Hospital
    Hong Kong, 999077, Hong Kong
    Recruiting
    • Molly Li · Principal investigator
  • Queen Mary Hospital
    Hong Kong, 999077, Hong Kong
    Recruiting
    • Victor Lee · Principal investigator
  • Hospital Umum Sarawak
    Kuching, Sarawak 93586, Malaysia
    Recruiting
    • Pei Jye Voon · Principal investigator
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
    Recruiting
    • Muthukkumaran Thiagarajan · Principal investigator
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
    Recruiting
    • Jiunn Liang Tan · Principal investigator
  • Institut Kanser Negara
    Putrajaya, 62250, Malaysia
    Recruiting
    • Yoke Fui Wong · Principal investigator
  • National Cancer Centre Singapore
    Singapore, 168583, Singapore
    Recruiting
    • Aaron Tan · Principal investigator
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
    Recruiting
    • Puey Ling Chia · Principal investigator
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
    Recruiting
    • Yu Jung Kim · Principal investigator
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Gyeonggi-do 16247, South Korea
    Recruiting
    • Byoung Yong Shim · Principal investigator
  • Chungbuk National University Hospital
    Cheongju-si, North Chungcheong 28644, South Korea
    Recruiting
    • Ki Hyeong Lee · Principal investigator
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, South Korea
    Recruiting
    • Min Hee Hong · Principal investigator
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Recruiting
    • Se-Hoon Lee · Principal investigator
  • ICO Badalona - Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Enric Carcereny Costa · Principal investigator
  • ICO l'Hospitalet - Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Noelia Vilariño Quintela · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Santiago Ponce Aix · Principal investigator
  • Hospital Regional Universitario de Málaga - Hospital Civil
    Málaga, 29011, Spain
    Recruiting
    • Manuel Cobo Dols · Principal investigator
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 80756, Taiwan
    Recruiting
    • Jen-Yu Hung · Principal investigator
  • Taichung Veterans General Hospital
    Taichung, 407219, Taiwan
    Recruiting
    • Tsung-Ying Yang · Principal investigator
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
    Recruiting
    • Chia-Chi Lin · Principal investigator
  • Taipei Medical University Hospital
    Taipei, 11031, Taiwan
    Recruiting
    • Chao-Hua Chiu · Principal investigator
  • Taipei Veterans General Hospital
    Taipei, 112201, Taiwan
    Recruiting
    • Yung-Hung Luo · Principal investigator
  • Phramongkutklao Hospital
    Thung Phaya Thai, Bangkok Metropolis 10400, Thailand
    Recruiting
    • Naiyarat Prasongsook · Principal investigator
  • Songklanagarind Hospital Prince of Songkla University
    Hat Yai, Changwat Songkhla 90100, Thailand
    Recruiting
    • Sarayut Geater · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jan 2029, 57 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 57 months is close to that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2029 → Oct 2029, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 13, 2026
StartActual
Mar 26, 2024
Primary completionEst.
Jan 1, 2029
CompletionEst.
Oct 1, 2029was Jan 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jan 1, 2029→Oct 1, 2029
Nov 3, 2026
Contact
Study contact's phone or email changed: •••4855→•••7849. See the current contact
across 2 updates, Nov 3, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Contact Study contact's phone or email changed: •••4855→•••7849. See the current contact
    + 1 other change: verification date
  2. Nov 3, 2026
    Study completion Jan 1, 2029→Oct 1, 2029
    Contact Study contact changed: s•••@voronoi.io · •••7849→i•••@voronoi.io · •••4855. See the current contact
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07699328
Lead sponsor
Voronoi, Inc
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Mar 26, 2024
Primary completion
Jan 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Trial Information
Contact
information_clinicaltrial_11@voronoi.io
+82 32 219 7849
Hongryul Jung, PhD
study director · Voronoi, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion